For research use only. Not for therapeutic Use.
LY223982 is a potent and specific inhibitor of leukotriene B4 receptor, with an IC50 of 13.2 nM against [3H]LTB4 binding to LTB4 receptor.
LY223982 is a potent and specific inhibitor of leukotriene B4 (LTB4) receptor, with an IC50 of 13.2 nM against [3H]LTB4 binding to LTB4 receptor. LY223982 is also a potent antagonist of the aggregation of human neutrophils by LTB4 (IC50, 100 nM)[1].
LY223982 inhibits transient leukopenia induced in rabbits with LTB4 (ED50, 3 mg/kg) but not with FMLP, and shows no agonist activity in any of the test systems[1].
| Catalog Number | I007795 |
| CAS Number | 117423-74-2 |
| Synonyms | 3-[3-(2-carboxyethyl)-4-[(E)-6-(4-methoxyphenyl)hex-5-enoxy]benzoyl]benzoic acid |
| Molecular Formula | C30H30O7 |
| Purity | ≥95% |
| InChI | InChI=1S/C30H30O7/c1-36-26-14-10-21(11-15-26)7-4-2-3-5-18-37-27-16-12-24(19-22(27)13-17-28(31)32)29(33)23-8-6-9-25(20-23)30(34)35/h4,6-12,14-16,19-20H,2-3,5,13,17-18H2,1H3,(H,31,32)(H,34,35)/b7-4+ |
| InChIKey | SYZSSLLFRVDRHL-QPJJXVBHSA-N |
| SMILES | COC1=CC=C(C=C1)C=CCCCCOC2=C(C=C(C=C2)C(=O)C3=CC(=CC=C3)C(=O)O)CCC(=O)O |
| Reference | [1]. Jackson WT, et al. Specific inhibition of leukotriene B4-induced neutrophil activation by LY223982. J Pharmacol Exp Ther. 1992 Dec;263(3):1009-14. |
